文献速递鼻科

草药干提取物BNO 1011改善兔慢性鼻窦炎模型的临床与黏液纤毛参数

Herbal dry extract BNO 1011 improves clinical and mucociliary parameters in a rabbit model of chronic rhinosinusitis.
PubMed 文献 · Int Forum Allergy Rhinol · 2019-01-18

在30只新西兰白兔慢性鼻窦炎模型中,随机口服安慰剂、BNO 1011低剂量(25 mg/kg/日)或高剂量(125 mg/kg/日)4周;BNO 1011显著减轻鼻窦浑浊、增强氯离子分泌、改善气道表面液体深度及组织学指标,高剂量改善更明显。

要点

  • BNO 1011高、低剂量组鼻窦浑浊CT评分均低于安慰剂组,高剂量改善最明显。
  • BNO 1011显著增强鼻窦电位差极化,并增加气道表面液体深度。
  • 高剂量BNO 1011组上皮厚度、上皮下厚度及黏膜下腺密度改善最明显。

核心结论

  • 草药干提取物BNO 1011改善兔慢性鼻窦炎模型的影像学、组织学和黏液纤毛清除参数。

研究设计与样本

  • 在30只新西兰白兔建立慢性鼻窦炎模型后,随机分为口服安慰剂组(n=10)、BNO 1011低剂量组(25 mg/kg/日,n=10)和高剂量组(125 mg/kg/日,n=10),给药4周。
  • 结局指标包括鼻窦浑浊(Kerschner兔鼻窦CT分级)、上颌窦上皮氯离子分泌(鼻窦电位差测定)、微光学相干断层扫描(μOCT)测气道表面液体深度及组织病理学黏膜下腺密度,由2名盲法研究者分析。

主要发现

  • 鼻窦浑浊:高剂量组1.21±0.63 vs 低剂量组1.26±0.37 vs 安慰剂组4.02±0.92(p=0.009),BNO 1011组均低于安慰剂组。
  • 鼻窦电位差极化:高剂量组-12.23±1.4 mV vs 低剂量组-12.0±3.0 mV vs 安慰剂组-4.1±1.1 mV(p=0.03)。
  • 气道表面液体深度:高剂量组4.08±0.06 μm vs 低剂量组4.05±0.06 μm vs 安慰剂组3.5±0.05 μm(事后分析,p<0.0001)。
  • 上皮厚度:高剂量组10.0±0.7 μm vs 低剂量组13.7±0.9 μm vs 安慰剂组21.1±2.3 μm(p<0.005);上皮下厚度:高剂量组63.1±6.6 μm vs 低剂量组103.2±6.7 μm vs 安慰剂组113.3±6.0 μm(p<0.001);黏膜下腺密度:高剂量组22.2±2.9% vs 低剂量组31.8±1.1% vs 安慰剂组43.8±1.7%(p<0.0001),高剂量组改善最明显。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enhancing chloride (Cl- ) secretion in sinus epithelia represents a novel therapeutic approach to chronic rhinosinusitis (CRS). Herbal dry extract BNO 1011 enhances mucociliary clearance (MCC) via upregulation of Cl- secretion in sinonasal cultures in vitro and murine epithelium in vivo. The objective of this study is to evaluate whether the BNO 1011 improves MCC and clinical parameters in a rabbit model of CRS. METHODS: After the development of CRS in 30 New Zealand white rabbits, animals were randomly assigned to receive oral placebo (n = 10), BNO 1011 (low dose [LD], 25 mg/kg/daily) (n = 10), or BNO1011 (high dose [HD], 125 mg/kg/daily) (n = 10) for 4 weeks. Outcomes included sinus opacification (Kerschner's rabbit sinus CT grade), maxillary epithelial Cl- secretion (sinus potential difference [PD] assay), airway surface liquid (ASL) depth using micro-optical coherence tomography (μOCT), and submucosal gland density (SMD) on histopathology. Outcome parameters were analyzed by 2 blinded investigators. RESULTS: BNO 1011 significantly cleared sinus opacification (HD = 1.21 ± 0.63, LD = 1.26 ± 0.37,) compared to placebo (4.02 ± 0.92) (p = 0.009). BNO 1011 resulted in markedly greater mean sinus PD polarization (HD = -12.23 ± 1.4 mV, LD = -12.0 ± 3.0 mV) when compared to rabbits treated with placebo (-4.1 ± 1.1 mV) (p = 0.03). ASL depth was significantly improved when treated with HD (4.08 ± 0.06 μm) and LD (4.05 ± 0.06 μm) compared to placebo (3.5 ± 0.05 μm) (post hoc analysis, p < 0.0001). Histologically, epithelial thickness (HD = 10.0 ± 0.7 μm; LD = 13.7 ± 0.9 μm; placebo = 21.1 ± 2.3 μm; p < 0.005), subepithelial thickness (HD = 63.1 ± 6.6 μm; LD = 103.2 ± 6.7 μm; placebo = 113.3 ± 6.0 μm; p < 0.001), and SMD (HD = 22.2 ± 2.9%; LD = 31.8 ± 1.1%; placebo = 43.8 ± 1.7%; p < 0.0001) were noticeably better with the HD. CONCLUSION: Herbal dry extract BNO 1011 improves radiographic, histologic, and MCC parameters in a rabbit model of CRS.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Cho DY, Skinner D, Mackey C, et al. Herbal dry extract BNO 1011 improves clinical and mucociliary parameters in a rabbit model of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019. PMID: 30657641. doi:10.1002/alr.22290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。